Form 8-K - Current report:
SEC Accession No. 0001171843-18-005271
Filing Date
2018-07-20
Accepted
2018-07-20 15:49:12
Documents
1
Period of Report
2018-07-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_072018.htm 8-K 16788
  Complete submission text file 0001171843-18-005271.txt   18025
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 18962461
SIC: 2836 Biological Products, (No Diagnostic Substances)